On May, 8th Traverse Health hosted an insightful Real-World Evidence workshop in collaboration with a major pharmaceutical company at Acibadem’s flagship hospital. This significant event provided an opportunity to fully assess Acibadem's advanced data infrastructure, explore new collaborative avenues, and identify potential synergies resulting from leveraging Traverse Health's expertise in healthcare data analytics.
We are excited to announce that the workshop concluded with the signing of an exclusive three-year RWE research cooperation agreement between Traverse Health and the Acibadem Hospital Group. This agreement marks a significant milestone by granting us unique access to some of the largest real-world patient datasets in the region, enabling us to derive unparalleled market insights for our pharmaceutical colleagues.
"Traverse Health has greatly contributed to refining our data management methodologies, which enhances our research capabilities across Acibadem operations. This in-depth data analysis helps us secure and anonymize patient information, enabling us to engage in groundbreaking clinical trials and research. These efforts are crucial for advancing clinical practices and ensuring the sustainability of our medical services," explained Prof Dr Efe Onganer of Acibadem.
This successful collaboration sets the foundation for further partnerships with our Big Pharma collaborators: by combining Traverse Health's expertise in data analytics with extensive research resources at Acibadem, we anticipate more innovative projects. These future collaborations will not only enhance our capabilities but also accelerate the development of new therapies and healthcare solutions that benefit patients worldwide.
Looking ahead, we are enthusiastic about the opportunities this partnership will create to improve patient outcomes and transform healthcare practices. Stay tuned for more updates as we continue to lead in healthcare innovation!
Explore the Future with Traverse Health
If you're considering how our solutions can benefit your research, contact us to learn more about our services and how we can help enhance your clinical trials.
We are excited to announce that the workshop concluded with the signing of an exclusive three-year RWE research cooperation agreement between Traverse Health and the Acibadem Hospital Group. This agreement marks a significant milestone by granting us unique access to some of the largest real-world patient datasets in the region, enabling us to derive unparalleled market insights for our pharmaceutical colleagues.
"Traverse Health has greatly contributed to refining our data management methodologies, which enhances our research capabilities across Acibadem operations. This in-depth data analysis helps us secure and anonymize patient information, enabling us to engage in groundbreaking clinical trials and research. These efforts are crucial for advancing clinical practices and ensuring the sustainability of our medical services," explained Prof Dr Efe Onganer of Acibadem.
This successful collaboration sets the foundation for further partnerships with our Big Pharma collaborators: by combining Traverse Health's expertise in data analytics with extensive research resources at Acibadem, we anticipate more innovative projects. These future collaborations will not only enhance our capabilities but also accelerate the development of new therapies and healthcare solutions that benefit patients worldwide.
Looking ahead, we are enthusiastic about the opportunities this partnership will create to improve patient outcomes and transform healthcare practices. Stay tuned for more updates as we continue to lead in healthcare innovation!
Explore the Future with Traverse Health
If you're considering how our solutions can benefit your research, contact us to learn more about our services and how we can help enhance your clinical trials.
